Usha Bughani
A5064564014- HER2/EGFR in Cancer Research
- Caveolin-1 and cellular processes
- Cancer, Hypoxia, and Metabolism
- Cancer Cells and Metastasis
- TGF-β signaling in diseases
- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Cancer Research and Treatments
The EGFR and TGFβ signaling pathways are important mediators of tumorigenesis, cross-talk between them contributes to cancer progression drug resistance. Therapies capable simultaneously targeting could help improve patient outcomes across various types. Here, we developed BCA101, an anti-EGFR IgG1 mAb linked extracellular domain human TGFβRII. "trap" fused the light chain in BCA101 did not sterically interfere with its ability bind EGFR, inhibit cell proliferation, or mediate...
<p>Supplementary data</p>
<div>Abstract<p>The EGFR and TGF-β signalling pathways are important mediators of tumorigenesis, crosstalk between them contributes to cancer progression drug resistance. Therapies capable simultaneously targeting could help improve patient outcomes across various types. Here, we developed BCA101, an anti-EGFR IgG1 monoclonal antibody linked extracellular domain human TGF-βRII. The “trap” fused the light chain in BCA101 did not sterically interfere with its ability bind EGFR,...
<p>Supplementary data</p>
<div>Abstract<p>The EGFR and TGFβ signaling pathways are important mediators of tumorigenesis, cross-talk between them contributes to cancer progression drug resistance. Therapies capable simultaneously targeting could help improve patient outcomes across various types. Here, we developed BCA101, an anti-EGFR IgG1 mAb linked extracellular domain human TGFβRII. The “trap” fused the light chain in BCA101 did not sterically interfere with its ability bind EGFR, inhibit cell...
<div>Abstract<p>The EGFR and TGF-β signalling pathways are important mediators of tumorigenesis, crosstalk between them contributes to cancer progression drug resistance. Therapies capable simultaneously targeting could help improve patient outcomes across various types. Here, we developed BCA101, an anti-EGFR IgG1 monoclonal antibody linked extracellular domain human TGF-βRII. The “trap” fused the light chain in BCA101 did not sterically interfere with its ability bind EGFR,...
<p>Supplementary data</p>
<p>Supplementary data</p>
<div>Abstract<p>The EGFR and TGFβ signaling pathways are important mediators of tumorigenesis, cross-talk between them contributes to cancer progression drug resistance. Therapies capable simultaneously targeting could help improve patient outcomes across various types. Here, we developed BCA101, an anti-EGFR IgG1 mAb linked extracellular domain human TGFβRII. The “trap” fused the light chain in BCA101 did not sterically interfere with its ability bind EGFR, inhibit cell...
<p>Supplementary data</p>
<p>Supplementary data</p>
Abstract Introduction: The suboptimal clinical efficacy EGFR-targeting therapeutics is attributed to both tumor intrinsic and microenvironment (TME) derived acquired (extrinsic) resistance mechanisms. Intrinsic factors include activation of other receptor tyrosine kinases key extrinsic mechanism the enhanced secretion immunosuppressive such as IL-10 TGF-β1. Here, we describe a first-in-class bifunctional monoclonal antibody fusion designed simultaneously target EGFR sequester TGF-β in TME....